{"id":3327,"date":"2020-01-24T12:52:32","date_gmt":"2020-01-24T17:52:32","guid":{"rendered":"https:\/\/www.bumc.bu.edu\/evanscenteribr\/?page_id=3327"},"modified":"2025-03-18T16:38:05","modified_gmt":"2025-03-18T20:38:05","slug":"precision-medicine-for-alzheimer-disease-and-related-disorders","status":"publish","type":"page","link":"https:\/\/www.bumc.bu.edu\/evanscenteribr\/the-arcs\/arc-programs\/precision-medicine-for-alzheimer-disease-and-related-disorders\/","title":{"rendered":"Precision Medicine for Alzheimer Disease and Related Disorders"},"content":{"rendered":"<h2>Co-Directors<\/h2>\n<p>Drs. Lindsay Farrer, Rhoda Au and Alice Cronin-Golomb<\/p>\n<h3>Synopsis<\/h3>\n<p>This ARC seeks to initiate a precision medicine program in Alzheimer disease (AD), a clinical area for which there is great need and broad expertise and resources at BU. We hypothesize that the reason current drugs used to treat AD are ineffective and clinical trial studies have largely failed is the assumption that AD is a single disease, when in fact, it has been well documented by clinical, imaging, neuropathological and genetic studies that AD is a heterogeneous disease. The primary aims of this ARC are to identify subtypes of AD within the Framingham Heart Study (FHS) dataset, validate these subtypes using other available data from the national AD Centers database and other public databases, investigate the biological underpinnings of these subtypes, and identify new therapeutic targets specific for these subtypes. As a first step, we will employ multiple computational strategies including \u201cBig Data\u201d analytics in collaboration with Clarivate Analytics (formerly known as Thomson Reuters) for identifying AD subtypes or risk factor profiles that are defined by profiles based on deep phenotyping (e.g., cognitive testing, medical history, brain imaging, biomarker, lifestyle) and \u2018Omic (e.g., genetic, genomic, methylomic, proteomic, and metabolomic) data. In subsequent funding periods, we propose to validate these subtypes in other datasets, derive stratification model(s) for assigning prospectively studied persons along the disease spectrum to disease subtypes for testing drug response and predicting prognosis, and evaluate experimentally the biological underpinnings of one or more subtypes and identify new therapeutic targets. This project introduces a very novel approach for extracting key information from very large and complex datasets that will define subtypes and risk profiles for AD. This program is uniquely suited at BU because of the availability of and experience working with the FHS dataset, world class clinical and basic science experts in AD, and opportunity to replicate and validate findings using local resources including the BU AD Center.<\/p>\n<p><strong>What we&#8217;re working on now &#8230;<\/strong><\/p>\n<p>Recycling of the amyloid precursor protein (APP) from the cell surface via the endocytic pathways plays a key role in the generation of amyloid \u00df-peptide (A\u00df), the accumulation of which is thought central to the pathogenesis of Alzheimer disease (AD).<\/p>\n<p>This ARC explores the role of vesicular sorting proteins and other genes involved\u00a0\u00a0 in protein trafficking in the etiology and pathophysiology of AD and other neurodegenerative disorders. The power of this ARC lies in its interdisciplinary expertise and ability to validate any finding using independent approaches of genetic epidemiology, cell biology, model systems and pathology.<\/p>\n<h5>HIGHLIGHTS<\/h5>\n<p>Notably, cognitive decline has been observed disproportionately in persons affected with MS and to a lesser extent with celiac disease, suggesting that these three diseases share a common immune or inflammatory pathway. Future studies of the protective mechanism of these <em>HLA<\/em> alleles may provide insight into the neurobiology of cognitive decline and dementia and novel therapeutic approaches for these disorders.<\/p>\n<div class=\"bu_collapsible_container \" aria-live=\"polite\" data-customize-animation=\"false\"><h4 class=\"bu_collapsible\" aria-expanded=\"false\"tabindex=\"0\" role=\"button\">5th Annual FHS-BAP Symposium<\/h4><div class=\"bu_collapsible_section\" style=\"display: none;\"><br \/>\n<b>Impact of the Exposome on Risk of Alzheimer\u2019s Disease and Related Dementias<\/b><\/p>\n<p>This event will be held virtually on April 14th, 2025, 12pm-4pm EST.<\/p>\n<p><span>Join us for the\u00a0<\/span><b>5th Annual Boston University Framingham Heart Study Brain Aging Program (FHS-BAP) Symposium (virtual) on Monday, April 14, 2025, from 12:00\u20134:00 PM (EST)<\/b><span>. This year\u2019s theme is\u00a0<\/span><b>\u201cImpact of the Exposome on Risk of Alzheimer\u2019s Disease and Related Dementias\u201d<\/b><span>, featuring six internationally renowned speakers presenting their latest research. <br style=\"clear: both;\" \/><br style=\"clear: both;\" \/>For any questions, please contact Maria Dudek at\u00a0<a title=\"mailto:medudek@bu.edu\" id=\"OWAca6f0507-4595-8920-4a8d-5085d7d69a5e\" href=\"mailto:medudek@bu.edu\" data-linkindex=\"1\">medudek@bu.edu<\/a>. We look forward to your participation<\/span><\/p>\n<p><img loading=\"lazy\" src=\"\/evanscenteribr\/files\/2025\/03\/Screenshot-2025-03-18-at-4.16.20-PM-1024x795.png\" alt=\"\" width=\"568\" height=\"441\" class=\"alignnone wp-image-5563\" srcset=\"https:\/\/www.bumc.bu.edu\/evanscenteribr\/files\/2025\/03\/Screenshot-2025-03-18-at-4.16.20-PM-1024x795.png 1024w, https:\/\/www.bumc.bu.edu\/evanscenteribr\/files\/2025\/03\/Screenshot-2025-03-18-at-4.16.20-PM-387x300.png 387w, https:\/\/www.bumc.bu.edu\/evanscenteribr\/files\/2025\/03\/Screenshot-2025-03-18-at-4.16.20-PM-768x596.png 768w, https:\/\/www.bumc.bu.edu\/evanscenteribr\/files\/2025\/03\/Screenshot-2025-03-18-at-4.16.20-PM-1536x1192.png 1536w, https:\/\/www.bumc.bu.edu\/evanscenteribr\/files\/2025\/03\/Screenshot-2025-03-18-at-4.16.20-PM-2048x1589.png 2048w\" sizes=\"(max-width: 568px) 100vw, 568px\" \/><\/p>\n<p><\/div>\n<\/div>\n\n<h4>ARC Members <br style=\"clear: both;\" \/><strong>(This ARC includes 20 faculty from various disciplines)<\/strong><\/h4>\n<p>Farrer, Lindsay, Medicine, Neurology, Ophthalmology, Epidemiology, Biostatistics<br \/>\nAu, Rhoda, Anatomy &amp; Neurobiology<br \/>\nCronin-Golomb, Alice, Psychological &amp; Brain Sciences<br \/>\nAbraham, Carmela, Biochemistry, Medicine<br \/>\nAdams, William, Pediatrics<br \/>\nBeffert, Uwe, Biology<br \/>\nBlusztajn, Jan, Pathology<br \/>\nBudson, Andrew, Cognitive Neuroscience<br \/>\nCheng, Christine, Biology<br \/>\nCruz-Martin, Alberto, Biology<br \/>\nFarrell, John, Medicine<br \/>\nGangopadhyay, Ashis, Mathematics &amp; Statistics<br \/>\nGoldstein, Lee, Psychiatry<br \/>\nHarris, David, Bichemistry<br \/>\nHasselmo, Michael, Psychological &amp; Brain Sciences<br \/>\nHo, Angela, Biology<br \/>\nIkezu, Tsuneya, Pharmacology<br \/>\nJun, Gyungah, Medcine<br \/>\nKalesan, Bindu, Transitional EPI<br \/>\nKolachalama, Vijaya, Medicine<br \/>\nKowall, Neil, Alzheimer Center<br \/>\nLin, Honghuang, Computational Biomedicine<br \/>\nLunetta, Kathryn, Biostatistics<br \/>\nLyons, Michael, Psychological &amp; Brain Sciences<br \/>\nMcKee, Ann, Neurology<br \/>\nMez, Jesse, Neurology<br \/>\nMorgan, Kathleen, Rehabilitation Sciences<br \/>\nMoss, Mark , Anatomy &amp; Neurobiology<br \/>\nQiu, Wendy, Psychiatry, Pharmacology<br \/>\nRyu, Hoon, Alzheimer Center<br \/>\nSchon, Karin, Anatomy &amp; Neurobiology<br \/>\nSherva, Richard, Medicine<br \/>\nStein, Thor, Pathology &amp; Lab Medicine<br \/>\nStern, Robert, Neurology<br \/>\nUnlu, Selim, Engineering<br \/>\nWolozin, Benjamin, Pharmacology<br \/>\nXia, Weiming, Pharmacology &amp; Experimental Therapeutics<br \/>\nZhang, Xiaoling, Medicine<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Co-Directors Drs. Lindsay Farrer, Rhoda Au and Alice Cronin-Golomb Synopsis This ARC seeks to initiate a precision medicine program in Alzheimer disease (AD), a clinical area for which there is great need and broad expertise and resources at BU. We hypothesize that the reason current drugs used to treat AD are ineffective and clinical trial [&hellip;]<\/p>\n","protected":false},"author":14042,"featured_media":0,"parent":3331,"menu_order":5,"comment_status":"closed","ping_status":"closed","template":"","meta":[],"_links":{"self":[{"href":"https:\/\/www.bumc.bu.edu\/evanscenteribr\/wp-json\/wp\/v2\/pages\/3327"}],"collection":[{"href":"https:\/\/www.bumc.bu.edu\/evanscenteribr\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/www.bumc.bu.edu\/evanscenteribr\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/www.bumc.bu.edu\/evanscenteribr\/wp-json\/wp\/v2\/users\/14042"}],"replies":[{"embeddable":true,"href":"https:\/\/www.bumc.bu.edu\/evanscenteribr\/wp-json\/wp\/v2\/comments?post=3327"}],"version-history":[{"count":13,"href":"https:\/\/www.bumc.bu.edu\/evanscenteribr\/wp-json\/wp\/v2\/pages\/3327\/revisions"}],"predecessor-version":[{"id":5566,"href":"https:\/\/www.bumc.bu.edu\/evanscenteribr\/wp-json\/wp\/v2\/pages\/3327\/revisions\/5566"}],"up":[{"embeddable":true,"href":"https:\/\/www.bumc.bu.edu\/evanscenteribr\/wp-json\/wp\/v2\/pages\/3331"}],"wp:attachment":[{"href":"https:\/\/www.bumc.bu.edu\/evanscenteribr\/wp-json\/wp\/v2\/media?parent=3327"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}